参考文献/References:
[1]陈亚红.2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J].中国全科医学,2022,25(11):1294-1304.[2]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[4]Barnes PJ.Inflammatory endotypes in COPD[J].Allergy,2019,74(7):1249-1256.[5]Kim HJ,Jung Y.The Emerging Role of Eosinophils as Multifunctional Leukocytes in Health and Disease[J].Immune Netw,2020,20(3):e24.[6]Ondari E,Calvino-Sanles E,First NJ,et al.Eosinophils and Bacteria, the Beginning of a Story[J].Int J Mol Sci,2021,22(15):8004.[7]Brightling C,Greening N.Airway inflammation in COPD: progress to precision medicine[J].Eur Respir J,2019,54(2):1900651.[8]Doyle AD,Mukherjee M,LeSuer WE,et al.Eosinophil-derived IL-13 promotes emphysema[J].Eur Respir J,2019,53(5):1801291.[9]Jogdand P,Siddhuraj P,Mori M,et al.Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue[J].Eur Respir J,2020,55(5):1900110.[10]Hartl S,Breyer MK,Burghuber OC,et al.Blood eosinophil count in the general population: typical values and potential confounders[J].Eur Respir J,2020,55(5):1901874.[11]Citgez E,van der Palen J,van der Valk P,et al.Stability in eosinophil categorisation during subsequent severe exacerbations of COPD[J].BMJ Open Respir Res,2021,8(1):e000960.[12]Long GH,Southworth T,Kolsum U,et al.The stability of blood Eosinophils in chronic obstructive pulmonary disease[J].Respir Res,2020,21(1):15.[13]Schumann DM,Tamm M,Kostikas K,et al.Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD[J].Chest,2019,156(3):456-465.[14]Greulich T,Tüffers J,Mager S,et al.High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis[J].Respir Res,2020,21(1):106.[15]Wang F,Yang L,Wang M,et al.Association between blood eosinophil count and bacterial infection and clinical outcomes in patients with severe exacerbations of chronic obstructive pulmonary disease[J].Chinese Medical Journal,2022,135(4):462-464.[16]Tan WC,Bourbeau J,Nadeau G,et al.High eosinophil counts predict decline in FEV1: results from the CanCOLD study[J].Eur Respir J,2021,57(5):2000838.[17]Wu HX,Zhuo KQ,Cheng DY.Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review[J].Front Med (Lausanne),2019,6:282.[18]Zeiger RS,Tran TN,Butler RK,et al.Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease[J].J Allergy Clin Immunol Pract,2018,6(3):944-954.e5.[19]Yun JH,Lamb A,Chase R,et al.Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease[J].J Allergy Clin Immunol,2018,141(6):2037-2047.e10.[20]Turato G,Semenzato U,Bazzan E,et al.Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2018,197(9):1216-1219.[21]Lipson DA,Barnhart F,Brealey N,et al.Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD[J].N Engl J Med,2018,378(18):1671-1680.[22]Pascoe S,Barnes N,Brusselle G,et al.Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial[J].Lancet Respir Med,2019,7(9):745-756.[23]Sivapalan P,Lapperre TS,Janner J,et al.Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial[J].Lancet Respir Med,2019,7(8):699-709.[24]Suissa S,Dell’Aniello S,Ernst P.Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study[J].Lancet Respir Med,2018,6(11):855-862.[25]Chalmers JD,Laska IF,Franssen FME,et al.Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline[J].Eur Respir J,2020,55(6):2000351. [26]Magnussen H,Lucas S,Lapperre T,et al.Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study[J].Respir Res,2021,22(1):25.[27]Chapman KR,Hurst JR,Frent SM,et al.Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial[J].Am J Respir Crit Care Med,2018,198(3):329-339.[28]Lan SH,Lai CC,Chang SP,et al.Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials[J].J Microbiol Immunol Infect,2022,55(1):26-35.[29]Pavord ID,Chapman KR,Bafadhel M,et al.Mepolizumab for Eosinophil-Associated COPD:Analysis of METREX and METREO[J].Int J Chron Obstruct Pulmon Dis,2021,16:1755-1770.[30]Zhang C,Wang Y,Zhang M,et al.Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis[J].Front Pharmacol,2021,12:754268.[31]Dagher R,Kumar V,Copenhaver AM,et al.Novel mechanisms of action contributing to benralizumab’s potent anti-eosinophilic activity[J].Eur Respir J,2022,59(3):2004306.[32]Criner GJ,Celli BR,Singh D,et al.Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies[J].Lancet Respir Med,2020,8(2):158-170.[33]Southworth T,Higham A,Kolsum U,et al.The relationship between airway immunoglobulin activity and eosinophils in COPD[J].J Cell Mol Med,2021,25(4):2203-2212.[34]Martinez-Garcia MA,Faner R,Oscullo G,et al.Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis[J].Am J Respir Crit Care Med,2020,201(9):1078-1085.[35]Vedel-Krogh S,Nordestgaard BG,Lange P,et al.Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD[J].Eur Respir J,2018,51(5):1800120.[36]Cui Y,Zhang W,Ma Y,et al.Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study[J].Respir Res,2021,22(1):301.[37]Martínez-Gestoso S,García-Sanz M,Calvo-?魣lvarez U,et al.Variability of blood eosinophil countand prognosis of COPDexacerbations[J].Annals of medicine (Helsinki),2021,53(1):1153-1159.
相似文献/References:
[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(18):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及
炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(18):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病
引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并
重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(18):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及
MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗
慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(18):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
[11]张凯新,杨林瀛.不同嗜酸性粒细胞水平的慢性阻塞性肺疾病急性加重期患者临床分析[J].医学信息,2021,34(08):85.[doi:10.3969/j.issn.1006-1959.2021.08.022]
ZHANG Kai-xin,YANG Lin-ying.Clinical Analysis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Different Levels of Eosinophils[J].Journal of Medical Information,2021,34(18):85.[doi:10.3969/j.issn.1006-1959.2021.08.022]
[12]于易琼,李 秀.血嗜酸性粒细胞及血尿酸在频繁急性加重表型慢性阻塞性肺疾病患者中的表达特征[J].医学信息,2022,35(02):6.[doi:10.3969/j.issn.1006-1959.2022.02.002]
YU Yi-qiong,LI Xiu.Expression Characteristics of Blood Eosinophils and Serum Uric Acid in Patientswith Frequent Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(18):6.[doi:10.3969/j.issn.1006-1959.2022.02.002]